What's New

Fully featured Heme analysis: DRAGEN secondary analysis and Connected Insights v5.1 heme interpretation capabilities
New breakthrough innovations within Illumina’s informatics solutions for oncology, DRAGEN secondary analysis and Illumina Connected Insights, now driv...

Connected Insights v5.1: Improved visualizations, heme interpretation, and streamlined curation capabilities
Latest updates to Connected Insights v5.1 provide our customers with breakthrough solutions for the most accurate and efficient analysis and interpret...

The growing case for whole-genome sequencing in all blood cancers
The comprehensive method provides improved detection and greater insight on the complex disease that impacts millions of people worldwide

Connected Insights-Local: v5.0 Now available on-premises via a DRAGEN™ server
Last month, Illumina released Connected Insights v5 on cloud, which unlocked key oncology variant interpretation functionality. Our clinical research ...

Connected Insights v5.0: Integration of AI models, interactive visualizations, and new variant curation capabilities
Connected Insights version 5.0 unlocks key new functionality for somatic oncology research applications, including AI algorithms to support variant pr...

Connected Insights v4.0: OncoKB™, automated oncogenicity classification, powerful fusion variant interpretation tools, and more
Our most highly anticipated release to date, Connected Insights v4.0 provides users with new functionality enabling interpretation of somatic oncology...
Other Oncology News

Illumina announces expansion of TruSight Oncology portfolio
The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology

Illumina launches new oncology menu for NovaSeq X Series customers
Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers

Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRD
Last updated
Was this helpful?